^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HLA-A positive

    i
    Other names: HLA-A, Major Histocompatibility Complex, Class I, A, HLA Class I Histocompatibility Antigen, A Alpha Chain, HLAA, HLA Class I Histocompatibility Antigen, A-1 Alpha Chain, MHC Class I Antigen HLA-A Heavy Chain, Leukocyte Antigen Class I-A, Human Leukocyte Antigen A
    Entrez ID:
    3105
    Related biomarkers:
    Expression
    Mutation
    Others
    Associations

    News

    Trials
    6ms
    HLA-A+ tertiary lymphoid structures with reactivated tumor infiltrating lymphocytes are associated with a positive immunotherapy response in esophageal squamous cell carcinoma. (PubMed, Br J Cancer)
    HLA-A+ TLSs are present in ESCC tumor tissues. TLS-resident TIL-Ts with elevated expression of the APM signature may be reactivated. HLA-A+ TLSs and their major cellular components, TIL-Ts and TIL-Bs, may serve as biomarkers for ICB-treated ESCC patients.
    Journal • Tumor-infiltrating lymphocyte • IO biomarker
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CXCL13 expression • HLA-A positive
    12ms
    TEDOVA: OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC (clinicaltrials.gov)
    P2, N=180, Recruiting, ARCAGY/ GINECO GROUP | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    HLA-A2 positive • HLA-A positive
    |
    Keytruda (pembrolizumab) • Tedopi (OSE 2101)
    1year
    Gender Disparities in Allograft Access Due to HLA-Sensitization in Multiparous Women: Implications for Evaluation of Female Patients for Alternative Donor Transplantation (ASH 2023)
    Over 10% of transplanted pts were broadly & highly sensitized to HLA. The HLA-Ab burden was predominantly in parous females (33% of our pt cohort), most of whom had HLA-Abs with one-third of this group being both broadly & highly sensitized. Moreover, pts with a high HLA-Ab burden were the least likely to receive haplos, & thus these transplants were less common in multiparous females.
    Clinical
    |
    HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    HLA-A positive
    over1year
    Tebentafusp reprograms immunosuppressive tumor-associated M2 macrophages towards anti-tumoral M1 macrophages (ESMO 2023)
    Conclusions ImmTAC-mediated redirection of T cells reprograms pro-tumoral M2 macrophages towards anti-tumoral M1 macrophages in vitro and in tebentafusp-treated mUM patients. These results demonstrate how tebentafusp re-shapes the tumor microenvironment to enhance the anti-tumor activity of T cells.
    IO biomarker
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CD163 (CD163 Molecule) • IRF4 (Interferon regulatory factor 4) • CD40 (CD40 Molecule) • MRC1 (Mannose Receptor C-Type 1) • CD80 (CD80 Molecule)
    |
    HLA-A*02:01 • HLA-A*02 • CD163 expression • HLA-A2 positive • HLA-A positive
    |
    Kimmtrak (tebentafusp-tebn)
    over2years
    A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation (clinicaltrials.gov)
    P1, N=63, Recruiting, TScan Therapeutics, Inc.
    New P1 trial
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02 • HLA-A2 positive • HLA-A positive
    |
    melphalan • TSC-100 • TSC-101
    almost4years
    Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Shenzhen BinDeBio Ltd. | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> May 2021
    Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin) • CTAG1B (Cancer/testis antigen 1B)
    |
    MSLN positive • HLA-A positive
    |
    multi-target gene-modified CAR-T/TCR-T cell immunotherapy